Cargando…
Cupriavidus necator-Produced Polyhydroxybutyrate/Eudragit FS Hybrid Nanoparticles Mitigates Ulcerative Colitis via Colon-Targeted Delivery of Cyclosporine A
Polyhydroxybutyrate (PHB) has emerged as a novel material for replacing various plastics used in the medical field. However, its application as a drug-delivery carrier for colitis-targeted delivery has not been explored. In this study, we used biosynthesized PHB combined with Eudragit FS (EFS) and c...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787777/ https://www.ncbi.nlm.nih.gov/pubmed/36559305 http://dx.doi.org/10.3390/pharmaceutics14122811 |
_version_ | 1784858594267627520 |
---|---|
author | Lee, Juho Saparbayeva, Aruzhan Hlaing, Shwe Phyu Kwak, Dongmin Kim, Hyunwoo Kim, Jihyun Lee, Eun Hee Yoo, Jin-Wook |
author_facet | Lee, Juho Saparbayeva, Aruzhan Hlaing, Shwe Phyu Kwak, Dongmin Kim, Hyunwoo Kim, Jihyun Lee, Eun Hee Yoo, Jin-Wook |
author_sort | Lee, Juho |
collection | PubMed |
description | Polyhydroxybutyrate (PHB) has emerged as a novel material for replacing various plastics used in the medical field. However, its application as a drug-delivery carrier for colitis-targeted delivery has not been explored. In this study, we used biosynthesized PHB combined with Eudragit FS (EFS) and cyclosporine A (CSA) to develop pH-responsive controlled CSA-releasing nanoparticles (CSA-PENPs) for colitis-targeted drug delivery and demonstrated its enhanced therapeutic efficacy in a dextran sulfate sodium (DSS)-induced murine colitis model. PHB was successfully biosynthesized in the bacterium Cupriavidus necator, as demonstrated by (1)H-NMR and FT-IR analyses. CSA-PENPs were fabricated via the oil-in-water emulsion solvent evaporation method. Owing to the potent pH-responsive and sustained drug release properties provided by PHB and EFS, CSA-PENPs could deliver a sufficient amount of CSA to inflamed tissues in the distal colon; in contrast, CSA-loaded EFS nanoparticles displayed premature burst release before reaching the target site. Due to enhanced CSA delivery to colitis tissues, CSA-PENPs exhibited potent anti-inflammatory effects in the DSS-induced murine colitis model. Overall, CSA-PENPs could be a promising drug-delivery system for treating ulcerative colitis. |
format | Online Article Text |
id | pubmed-9787777 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97877772022-12-24 Cupriavidus necator-Produced Polyhydroxybutyrate/Eudragit FS Hybrid Nanoparticles Mitigates Ulcerative Colitis via Colon-Targeted Delivery of Cyclosporine A Lee, Juho Saparbayeva, Aruzhan Hlaing, Shwe Phyu Kwak, Dongmin Kim, Hyunwoo Kim, Jihyun Lee, Eun Hee Yoo, Jin-Wook Pharmaceutics Article Polyhydroxybutyrate (PHB) has emerged as a novel material for replacing various plastics used in the medical field. However, its application as a drug-delivery carrier for colitis-targeted delivery has not been explored. In this study, we used biosynthesized PHB combined with Eudragit FS (EFS) and cyclosporine A (CSA) to develop pH-responsive controlled CSA-releasing nanoparticles (CSA-PENPs) for colitis-targeted drug delivery and demonstrated its enhanced therapeutic efficacy in a dextran sulfate sodium (DSS)-induced murine colitis model. PHB was successfully biosynthesized in the bacterium Cupriavidus necator, as demonstrated by (1)H-NMR and FT-IR analyses. CSA-PENPs were fabricated via the oil-in-water emulsion solvent evaporation method. Owing to the potent pH-responsive and sustained drug release properties provided by PHB and EFS, CSA-PENPs could deliver a sufficient amount of CSA to inflamed tissues in the distal colon; in contrast, CSA-loaded EFS nanoparticles displayed premature burst release before reaching the target site. Due to enhanced CSA delivery to colitis tissues, CSA-PENPs exhibited potent anti-inflammatory effects in the DSS-induced murine colitis model. Overall, CSA-PENPs could be a promising drug-delivery system for treating ulcerative colitis. MDPI 2022-12-15 /pmc/articles/PMC9787777/ /pubmed/36559305 http://dx.doi.org/10.3390/pharmaceutics14122811 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lee, Juho Saparbayeva, Aruzhan Hlaing, Shwe Phyu Kwak, Dongmin Kim, Hyunwoo Kim, Jihyun Lee, Eun Hee Yoo, Jin-Wook Cupriavidus necator-Produced Polyhydroxybutyrate/Eudragit FS Hybrid Nanoparticles Mitigates Ulcerative Colitis via Colon-Targeted Delivery of Cyclosporine A |
title | Cupriavidus necator-Produced Polyhydroxybutyrate/Eudragit FS Hybrid Nanoparticles Mitigates Ulcerative Colitis via Colon-Targeted Delivery of Cyclosporine A |
title_full | Cupriavidus necator-Produced Polyhydroxybutyrate/Eudragit FS Hybrid Nanoparticles Mitigates Ulcerative Colitis via Colon-Targeted Delivery of Cyclosporine A |
title_fullStr | Cupriavidus necator-Produced Polyhydroxybutyrate/Eudragit FS Hybrid Nanoparticles Mitigates Ulcerative Colitis via Colon-Targeted Delivery of Cyclosporine A |
title_full_unstemmed | Cupriavidus necator-Produced Polyhydroxybutyrate/Eudragit FS Hybrid Nanoparticles Mitigates Ulcerative Colitis via Colon-Targeted Delivery of Cyclosporine A |
title_short | Cupriavidus necator-Produced Polyhydroxybutyrate/Eudragit FS Hybrid Nanoparticles Mitigates Ulcerative Colitis via Colon-Targeted Delivery of Cyclosporine A |
title_sort | cupriavidus necator-produced polyhydroxybutyrate/eudragit fs hybrid nanoparticles mitigates ulcerative colitis via colon-targeted delivery of cyclosporine a |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787777/ https://www.ncbi.nlm.nih.gov/pubmed/36559305 http://dx.doi.org/10.3390/pharmaceutics14122811 |
work_keys_str_mv | AT leejuho cupriavidusnecatorproducedpolyhydroxybutyrateeudragitfshybridnanoparticlesmitigatesulcerativecolitisviacolontargeteddeliveryofcyclosporinea AT saparbayevaaruzhan cupriavidusnecatorproducedpolyhydroxybutyrateeudragitfshybridnanoparticlesmitigatesulcerativecolitisviacolontargeteddeliveryofcyclosporinea AT hlaingshwephyu cupriavidusnecatorproducedpolyhydroxybutyrateeudragitfshybridnanoparticlesmitigatesulcerativecolitisviacolontargeteddeliveryofcyclosporinea AT kwakdongmin cupriavidusnecatorproducedpolyhydroxybutyrateeudragitfshybridnanoparticlesmitigatesulcerativecolitisviacolontargeteddeliveryofcyclosporinea AT kimhyunwoo cupriavidusnecatorproducedpolyhydroxybutyrateeudragitfshybridnanoparticlesmitigatesulcerativecolitisviacolontargeteddeliveryofcyclosporinea AT kimjihyun cupriavidusnecatorproducedpolyhydroxybutyrateeudragitfshybridnanoparticlesmitigatesulcerativecolitisviacolontargeteddeliveryofcyclosporinea AT leeeunhee cupriavidusnecatorproducedpolyhydroxybutyrateeudragitfshybridnanoparticlesmitigatesulcerativecolitisviacolontargeteddeliveryofcyclosporinea AT yoojinwook cupriavidusnecatorproducedpolyhydroxybutyrateeudragitfshybridnanoparticlesmitigatesulcerativecolitisviacolontargeteddeliveryofcyclosporinea |